Anti-LCN2 antibody treatment is associated with attenuated hearing loss and blood–labyrinth barrier disruption in a mouse model of chronic kidney disease
Medicine
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.